Clinical Trials on Refractory B-Cell Non-Hodgkin Lymphoma in China

Total 1051 results

RenJi Hospital

Recruiting

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Ruijin Hospital

Recruiting

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid Tumors | Relapsed/Refractory B-cell Lymphoma

China
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (R2-GOD)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Shanghai Tongji Hospital, Tongji University School...
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
Peking University
University of Florida

Unknown

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)

B-cell Lymphomas

China
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
Zhejiang Teruisi Pharmaceutical Inc.

Recruiting

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

CD20-positive B-cell Non-Hodgkin Lymphoma

China
Tianjin Medical University Cancer Institute and...
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Non-Hodgkin's B-cell Lymphoma

China
oubai, MD/PhD

Recruiting

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Diffuse Large B Cell Lymphoma | Follicular Lymphoma Grade 3B

China
First Affiliated Hospital of Zhejiang University
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Non-Hodgkin's B-cell Lymphoma

China
Shenzhen University General Hospital

Recruiting

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma (CAR-T)

Non-hodgkin Lymphoma,B Cell

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma (ZR2-CHOP)

Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
BeiGene

Completed

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

China
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Fujian Medical University

Recruiting

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

China
Bayer

Completed

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Non-Hodgkin's Lymphoma | Lymphoma, Low-Grade

Japan
Regeneron Pharmaceuticals

Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

B-cell Non-Hodgkin Lymphoma (NHL)

United States, Korea, Republic of, China, Spain, Japan, United Kingdom, France, Taiwan, Singapore, Italy, Australia, Canada, Germany, Poland
BeiGene

Recruiting

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Fudan University

Active, not recruiting

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Lymphoma, Non-Hodgkin

China
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | B-cell Non-Hodgkin's Lymphoma (B-NHL) | T-Cell Leukemia/Lymphoma, Adult | B-cell Acute Lymphoblastic Leukemia (B-ALL)

China
Chinese PLA General Hospital
Shenzhen University General Hospital; Shenzhen University

Unknown

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

China
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Antengene Corporation

Recruiting

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (SWATCH)

Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Multiple Myeloma | B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

China
Chongqing University Cancer Hospital

Recruiting

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

China
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
Second Affiliated Hospital, School of Medicine,...
Hangzhou Rongu Biotechnology Co., Ltd.

Recruiting

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Tarapeutics Science Inc.

Recruiting

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Advanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

China
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences; Navy General Hospital, Beijing

Unknown

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China

Clinical Trials on Refractory B-Cell Non-Hodgkin Lymphoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations